sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has reported its position regarding shares in Avadel Pharmaceuticals plc. The disclosure aligns with the requirements of the Irish Takeover Panel Act, 1997. Per the filing dated 16 January 2026, Vanguard holds 5,855,442 ordinary shares in Avadel, representing a 6.01% stake in the company.
The disclosure, made under Rule 8.3, does not indicate any additional parties involved in dealings. Additionally, the report reveals a purchase of 3,423 shares at a price of 21.48 USD per share. No cash-settled or stock-settled derivative positions are currently reported.
Vanguard states no existing indemnities, options, or formal agreements concerning these securities. There are no supplemental forms attached, reinforcing the straightforward nature of its stake disclosure. These filings ensure transparency in Vanguard's investment activities with respect to Avadel Pharmaceuticals.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.